StockGuru Announces a New Executive Interview With Stephen Ross of Remedent Inc.


DALLAS, Jan. 6, 2011 (GLOBE NEWSWIRE) -- StockGuru.com announces a new executive interview featuring Stephen F. Ross, the Chief Financial Officer of Remedent Inc. (OTCBB:REMI). In the interview, Mr. Ross speaks to StockGuru Publisher John Pentony, and delivers an insightful update on Remedent's rapid growth story as reflected in the Company's most recent SEC filings. In those filings, the Company shows a sales increase of 74% for the three months ending September 30, 2010 when compared to the same period a year earlier and a sales increase of 66% for the six months ending September 30, 2010 when compared to the same period a year earlier.

In the interview, Mr. Ross comments on Remedent's recent success in its move to profitability. He commented that the Company is moving, "from red on to black, and really we have not even scratched the surface yet as we are just now opening in growing markets."

When Remedent opens new locations for their GlamSmile Retail Studios, Mr. Ross commented, "We have never opened with less than a hundred thousand dollars in revenue in our first month of business." He further stated that they accomplished this without a prior customer list or a prior base of customers. He added, "This shows that the demand for our services and our products really exists and is very, very strong. Especially in China."

To listen to the interview, please visit:

http://www.stockguru.com/2011/1/remi-interview/

Remedent, Inc. specializes in the research, development, manufacturing and marketing of oral care and domestic dentistry products. The company serves the professional dental industry with breakthrough technology for dental veneers. These products are supported by a line of professional veneer whitening and teeth sensitivity solutions. Headquartered in Belgium, Remedent distributes its products to more than 35 countries worldwide. For more information, go to http://www.remedent.com.

This press release contains projections of future results and other forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Important factors that may cause actual results and outcomes to differ materially from those contained in the projections and forward-looking statements included in this press release are described in our publicly filed reports. Factors that could cause these differences include, but are not limited to, the acceptance of our products, lack of revenue growth, failure to realize profitability, inability to raise capital and market conditions that negatively affect the market price of our common stock. The Company disclaims any responsibility to update any forward-looking statements.

Remedent, Inc. Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract on December 21, 2010. REMI has agreed to compensate us five thousand dollars for coverage. We have taken no free trading shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold only restricted shares and will not register or sell these shares at anytime during the promotional period. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.


            

Kontaktdaten